Featured Content

Ahead of the Pharma Contract Manufacturing Summit 2023, Pharma IQ spoke exclusively to David Berry, Head of Digital Business Systems - Pharma, CPI about connecting automation to a QP dashboard at the MMIC, to help you discover new opportunities and solutions to your current pharma manufacturing challenges. 

Fill in the form below to access David's exclusive insights >>>

The importance of selecting the right CMO/CDMO partnership is critical, as the benefits go beyond significant cost reduction, there is also the potential to improve and develop more strategies for pharmaceutical companies. But only if a mutually collaborative, open and trusting relationship is built.

Ahead of the Pharma Contract Manufacturing Summit 2023, we spoke exclusively to Federica Fraschetti, Associate Director, Focus Factory Leader – Bio ExM, MSD about the key do’s and don’ts when selecting a CMO, to help you find the right fit for your pharmaceutical company.

Download the full article here >>>

When selecting partners, meeting stringent sustainability criteria along entire pharmaceutical supply chains has far-reaching environmental, economic and reputational benefits. Whilst adding a sustainability criteria to the bidding process is a positive one for driving more responsible operations across the entire pharmaceutical industry, it simultaneously amplifies the complexity of selecting a Contract Manufacturing Organization (CMO).

Unlock the report to delve into vital statistics and expert insights, covering:

• Stringent selection criteria: understand the pivotal role stringent criteria play in shaping responsible and sustainable partnerships
• Bottom line benefits: explore the tangible economic advantages that sustainable practices bring to the forefront of your pharmaceutical operations
• Technology for greener supply chains: navigate the latest innovations driving sustainability in pharmaceutical supply chains and stay ahead in the industry

Topped up with expert commentary from industry leaders: Philip Coetzee, Director CMO Management, Daiichi Sankyo and Gregory Vanderwinden, Associate Director – External Manufacturing EU, MSD.

Elevate your CMO selection process and lead the way towards a greener, more sustainable pharmaceutical future.  Access the report now.

As pharmaceutical businesses worldwide become more aware of the importance of meeting sustainability goals, it is inevitable that this will become a consideration when selecting a contract manufacturing organisation (CMO) or contract development and manufacturing organisation (CDMO). But it’s important to ensure that meeting sustainability goals when collaborating with external partners is genuine rather than just greenwashing.

That's why ahead of Pharma Contract Manufacturing 2024 we have collated exclusive insights on CMO Selection - Making Sustainability a Top Priority.

Access the infographic and dive into:

• The Top 5 considerations for sustainable CMO selection
• Key questions for the selection process
• Changing the culture strategy
• Examining your Scope 3 emissions
• Real-world examples of setting measurable targets
• Looking ahead: The big picture benefits

Due to the pandemic, the medical needs of populations worldwide are increasing and there is a huge demand for pharmaceutical products, causing CMOs and CDMOs to be increasingly sought after by pharmaceutical companies for their specialist equipment, facilities, labour force and cost-effective production. However, as large pharmaceutical companies start to develop in-house manufacturing capabilities, there is more and more competition between CMOs and CDMOs to prove they are the best partner.

Ahead of this year's Pharma Contract Manufacturing 2022 event, we spoke to Ulrich Rümenapp, Head of Launch Preparation and Coordination at Bayer AG, about the importance of maintaining positive partnerships with CMOs and CDMOs, to help you create and maintain positive partnerships with your CMOs and CDMOs, and build industry resilience.

Download the full interview now >>

Additional benefits to downloading the full interview:

• Discover how the last 18 months has impacted CMO and/or CDMO partnerships
• Learn about the greatest challenges of complex product manufacturing, and the top tips for overcoming these challenges
• Find out more about the benefits and opportunities of CMO and/or CDMO partnerships
• A summary of the key initiatives for maintaining positive CMO and/or CDMO partnerships over the next 2 years

It’s hardly surprising that pharma companies are changing the way they work with external partners, with increasing pressures on quality, cost and scalability determining not only which manufacturers the industry outsources to, but how many partners to take on.

With this in mind, Pharma IQ spoke with Simon Hendry, BD Director, Adare Pharmaceuticals, on the current challenges and best practices of streamlining external networks of CMOs. Hendry, speaks in-depth on the critical success factors you need to uncover in the selection process and how to manage emerging markets, all whilst ensuring quality isn’t compromised.

Download the full interview on the right >>

Other key benefits to downloading the full interview:

• Analysing what changes need to be made over the next 12-24 months to meet the main challenges of the industry
• Understanding the best practices for building a successful CMO partnership
• Exploring what criteria is most valuable to the industry when selecting a CDMO
  

Present your boss with this customizable letter detailing the reasons why you should attend Pharma Contract Manufacturing 2024 from 09 – 11 April, 2024 in Berlin, Germany. Just download the letter template below, adjust as necessary (or edit as needed) and submit! We hope to welcome you there!